House Committee Passes Alzheimer's Blood Test Coverage Bill
The legislation creates a pathway for Medicare to cover FDA-cleared blood tests for early Alzheimer's detection.
Updated on Oct. 29, 2026 in Alzheimer’s
Live Poll
Should Medicare cover new blood tests for the early detection of Alzheimer's disease?
On September 16, 2026, the U.S. House Ways and Means Committee unanimously passed the Alzheimer's Screening and Prevention Act. This bill seeks to expand Medicare coverage for early detection blood tests to provide an alternative to spinal taps or PET scans.
Why it matters
Current Medicare law restricts coverage for many preventive health services, leaving patients to rely on invasive or costly diagnostic methods. This legislation aims to streamline access to less burdensome blood testing for individuals at elevated risk of the disease.
The legislation currently has 230 House cosponsors and 50 Senate cosponsors. It limits coverage for the blood tests to individuals identified as being at an elevated risk.
The players
U.S. House Ways and Means Committee
This is the chief tax-writing committee of the House of Representatives that also holds jurisdiction over Medicare and Social Security legislation.
House Energy and Commerce Subcommittee
This body oversees legislative issues related to national energy policy, telecommunications, and public health standards.
The details
The bill creates a transition period for Medicare coverage that will last until a formal, traditional coverage decision is issued by federal health authorities. Blood-based diagnostics offer a less invasive alternative for patients compared to the current standard of spinal taps or amyloid PET scans.
Timeline
The FDA cleared the first Alzheimer's blood test in May 2025.
The House Energy and Commerce Subcommittee held a hearing on the legislation on September 15, 2026.
The Ways and Means Committee passed the bill on September 16, 2026.
The Big Picture
This legislation represents a fundamental shift from the restrictive Medicare coverage protocols established by the Social Security Act. It establishes a new precedent for how federal programs integrate rapidly evolving diagnostic technologies into patient care.
Medicare beneficiaries currently facing Alzheimer's risk may soon gain access to blood tests as a less invasive alternative to spinal taps. This change could lower the physical and financial barriers to early disease detection for millions of older adults.
The takeaway
Early detection remains critical as the landscape for Alzheimer's diagnostics evolves from invasive procedures to simple blood tests. Patients should consult their healthcare providers about emerging testing options as federal policy continues to shift toward broader coverage.
What happens next
The legislation must pass the full House of Representatives and the Senate before the 119th Congress concludes to avoid expiring.
Further reading
Learn more about the latest diagnostic options and care standards on the Alzheimer’s page.
Source note: This article includes information reported by Atlanta Magazine.
Live Poll
Should Medicare cover new blood tests for the early detection of Alzheimer's disease?
